United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - dihydrocodeine bitartrate 32 mg - acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the relief of moderate to moderately severe pain. this combination product is contraindicated in persons with hypersensitivity to dihydrocodeine, codeine, acetaminophen, caffeine, or any of the inactive components listed above, or any situation where opioids are contraindicated including significant respiratory depression (in unmonitored settings or in the absence of resuscitative equipment), acute or severe bronchial asthma or hypercapnia, and paralytic ileus. this combination product is subject to the provisions of the controlled substance act, and has been placed in schedule iii. dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. like other opioid analgesics, dihydrocodeine may produce subjective effects other than analgesia (e.g., euphoria, relaxation), which may contribute to abuse by some patients. psychological dependence, physical dependence, and tolerance may d

United States - English - NLM (National Library of Medicine)

mikart, inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (codeine - unii:q830pw7520) - tablet - 712.8 mg - acetaminophen, caffeine and dihydrocodeine bitartrate tablets are indicated for the relief of moderate to moderately severe pain. this combination product is contraindicated in patients with hypersensitivity to dihydrocodeine, codeine, acetaminophen, caffeine, or any of the inactive components listed above, or in any situation where opioids are contraindicated including significant respiratory depression (in unmonitored settings or in the absence of resuscitative equipment), acute or severe bronchial asthma or hypercapnia, and paralytic ileus. this combination product is subject to the provisions of the controlled substance act, and has been placed in schedule iii. dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. like other opioid analgesics, dihydrocodeine may produce subjective effects other than analgesia (e.g., euphoria, relaxation), which may contribute to abuse by some patients. psychological dependence, physical dependence, and tolerance ma

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - dihydrocodeine hydrogen tartrate 60mg equivalent to dihydrocodeine 40 mg - modified release tablet - 60 mg - active: dihydrocodeine hydrogen tartrate 60mg equivalent to dihydrocodeine 40 mg excipient: cetostearyl alcohol hyetellose lactose monohydrate magnesium stearate purified talc - dhc continus is indicated for the management of severe pain where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and -the pain is opioid-responsive, and -requires daily, continuous, long term treatment. dhc continus is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. dhc continus is not indicated as an as-needed (prn) analgesia.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare international ltd - dihydrocodeine tartrate - modified-release tablet - 60mg

Malta - English - Medicines Authority

wockhardt uk limited - dihydrocodeine tartrate - tablet - dihydrocodeine tartrate 30 mg - analgesics

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - dihydrocodeine hydrogen tartrate 60mg - modified release tablet - 60 mg - active: dihydrocodeine hydrogen tartrate 60mg excipient: calcium sulfate dihydrate copovidone glyceryl behenate sodium stearyl fumarate - dihydrocodeine controlled release actavis tablets are recommended for use in the treatment of post-operative pain, and pain associated with cancer.

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - dihydrocodeine tartrate - tablet - dihydrocodeine tartrate 30 mg - analgesics

United States - English - NLM (National Library of Medicine)

larken laboratories inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855) - acetaminophen 325 mg - acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve acetaminophen, caffeine, and dihydrocodeine bitartrate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are contraindicated for: - all children younger than 12 years of age [see warnings and precautions ] - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see warnings and p

United States - English - NLM (National Library of Medicine)

atland pharmaceuticals, llc - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e), dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855) - acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings], reserve acetaminophen, caffeine, and dihydrocodeine bitartrate tablets for use in patients for whom alternative  treatment options [e.g., non-opioidanalgesics] - have not been tolerated, or are not expected to be tolerated - have not provided adequate analgesia, or are not expected to provide adequate analgesia acetaminophen, caffeine and dihydrocodeine bitartrate tablets are contraindicated for: all - children younger than 12 years of age [see  warnings and precautions ] - post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see  warnings and precau

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - dihydrocodeine tartrate -